MIA is a potential biomarker for tumour load in neurofibromatosis type 1

• Published in: BMC medicine 2011-07, Vol.9 (1), p.82-82, Article 82
• Main Authors: Kolanczyk, Mateusz, Mautner, Victor, Kossler, Nadine, Nguyen, Rosa, Kühnisch, Jirko, Zemojtel, Tomasz, Jamsheer, Aleksander, Wegener, Eike, Thurisch, Boris, Tinschert, Sigrid, Holtkamp, Nikola, Park, Su-Jin, Birch, Patricia, Kendler, David, Harder, Anja, Mundlos, Stefan, Kluwe, Lan
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Animals; Biomarkers, Tumor - analysis; Care and treatment; Complications and side effects; Diagnosis; Disease Models, Animal; Extracellular Matrix Proteins - analysis; Female; Genetic aspects; Genetic markers; Humans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplasm Proteins - analysis; Neurofibromatosis; Neurofibromatosis 1 - pathology; Physiological aspects; Tumor Burden; Young Adult
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/1741-7015-9-82

Neurofibromatosis type 1 (NF1) is a frequent genetic disease characterized by multiple benign tumours with increased risk for malignancy. There is currently no biomarker for tumour load in NF1 patients. In situ hybridization and quantitative real-time polymerase reaction were applied to investigate expression of cartilage-specific genes in mice bearing conditional inactivation of NF1 in the developing limbs. These mice do not develop tumours but recapitulate aspects of NF1 bone dysplasia, including deregulation of cartilage differentiation. It has been recently shown that NF1 tumours require for their growth the master regulator of cartilage differentiation SOX9. We thus hypothesized that some of the cartilage-specific genes deregulated in an Nf1Prx1 mouse model might prove to be relevant biomarkers of NF1 tumours. We tested this hypothesis by analyzing expression of the SOX9 target gene product melanoma-inhibitory activity/cd-rap (MIA) in tumour and serum samples of NF1 patients. Increased expression of Mia was found in Nf1-deficient cartilage in mice. In humans, MIA was expressed in all NF1-related tumours and its serum levels were significantly higher in NF1 patients than in healthy controls. Among NF1 patients, MIA serum levels were significantly higher in those with plexiform neurofibromas and in those with large number of cutaneous (> 1,000) or subcutaneous (> 100) neurofibromas than in patients without such tumours. Most notably, MIA serum levels correlated significantly with internal tumour burden. MIA is a potential serum biomarker of tumour load in NF1 patients which could be useful in following the disease course and monitoring the efficacy of therapies.